Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for suppressing glucagon secretion of SGLT2 inhibitor

A glucagon and inhibitor technology, which is applied to medical preparations containing active ingredients, pharmaceutical formulations, organic active ingredients, etc., can solve the problem of increased glucagon secretion, unclear mechanism of glucagon secretion, etc. question

Inactive Publication Date: 2017-05-24
ASTRAZENECA AB
View PDF20 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

DeFronzo and Ferranini's paper shows that treatment with SGLT2 inhibitors leads to increased glucagon secretion
The mechanism by which SGLT2 inhibitors stimulate glucagon secretion is unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for suppressing glucagon secretion of SGLT2 inhibitor
  • Method for suppressing glucagon secretion of SGLT2 inhibitor
  • Method for suppressing glucagon secretion of SGLT2 inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0074] The following is an illustration of the invention.

[0075] Adult patients with type 2 diabetes mellitus (T2DM) and HbA1c levels greater than or equal to 8% and less than or equal to 12% who had been on stable metformin therapy for at least 8 weeks at screening were randomized 1:1:1 Receive saxagliptin (5 mg / day) and dapagliflozin (10 mg / day) plus metformin XR (1500-2000 mg / day) dose, saxagliptin (5 mg / day) and placebo plus metformin XR (1500-2000 mg / day) dose, or dapagliflozin (10 mg / day) and placebo plus metformin XR (1500-2000 mg / day) dose for 24 weeks.

[0076] At the beginning of the 4-week run-in period, all patients were switched to the closest metformin XR dose (1,500-2,000 mg / day) during the run-in period and 24 weeks of treatment. Patients were then randomized to receive saxagliptin 5 mg / day and dapagliflozin 10 mg / day plus metformin (SAXA + DAPA + MET), saxagliptin 5 mg / day and placebo plus metformin (SAXA + MET) , or dapagliflozin 10 mg / day and placebo plu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods are provided for avoiding an increase in glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (SGLT2) inhibitor via the co-administration of a dipeptidyl peptidase IV (DPP IV) inhibitor. Additionally, methods are provided for normalizing the glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (SGLT2) inhibitor via the co-administration of a dipeptidyl peptidase IV (DPP IV) inhibitor. The present invention also relates to methods for treating diabetes, especially type 2 diabetes, as well as hyperglycemia, hyperinsulinemia, obesity, hypertriglyceridemia, syndrome X, diabetic complications, atherosclerosis and related diseases, with the method comprising administering the SGLT2 inhibitor and the dipeptidyl peptidase IV (DPP IV) inhibitor.

Description

[0001] This application claims the benefit of U.S. Provisional Application Serial Nos. 61 / 994,222 and 62 / 011,084, filed May 16, 2014, and June 12, 2014, respectively, which are incorporated by reference in their entirety In this article. technical field [0002] The present invention relates to a method of avoiding the increase in glucagon secretion associated with the administration of sodium glucose cotransporter 2 (SGLT2) inhibitors by coadministering dipeptidyl peptidase IV (DPP IV) inhibitors. The present invention also relates to a method of normalizing glucagon secretion associated with the administration of a sodium glucose cotransporter 2 (SGLT2) inhibitor by concomitant administration of a dipeptidyl peptidase IV (DPP IV) inhibitor. Furthermore, the invention relates to the treatment of diabetes mellitus, type 1 and type 2 diabetes, especially type 2 diabetes, as well as hyperglycemia, hyperinsulinemia, obesity, hypertriglyceridemia, syndrome X, diabetic complication...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/403A61P3/10A61P3/06A61P3/04A61P9/10A61P3/00A61K31/155A61K31/351
CPCA61K38/28A61K31/155A61K31/40A61K31/403A61K31/4985A61K31/522A61K31/70A61K31/7042A61K38/26A61K31/351A61P1/06A61P3/00A61P3/04A61P3/06A61P43/00A61P9/10A61P3/10A61K2300/00A61K45/06
Inventor B.希尔什伯格N.伊奎巴尔
Owner ASTRAZENECA AB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com